Related Experiment Video

Updated: Jul 26, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

ara-Cytidine acylates. Use of drug design predictors in structure-activity relationship correlation

W J Wechter, M A Johnson, C M Hall

    Journal of Medicinal Chemistry
    |April 1, 1975
    PubMed

    More Related Videos

    Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

    Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

    Published on: June 23, 2026

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

    Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

    Published on: May 9, 2025

    Related Concept Videos

    Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

    Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

    Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
    The direct-acting...
    Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

    Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

    Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
    Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
    Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

    Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

    Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
    Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

    Adrenergic Agonists: Chemistry and Structure-Activity Relationship

    Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
    Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
    Separation of the aromatic...
    Structure-Activity Relationships and Drug Design01:28

    Structure-Activity Relationships and Drug Design

    Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
    SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
    Drug Product Performance: In Vitro–In Vivo Correlation01:20

    Drug Product Performance: In Vitro–In Vivo Correlation

    In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...